---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261723"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:56:00.003656+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms

## Summary
- Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.
- Sokolove previously CMO-in-Residence at Roivant Sciences, SVP at GSK, Head of Immunology at AbbVie.
- Vor Bio emphasizes Telitacicept (dual BAFF/APRIL inhibitor) as near-term opportunity for autoimmune patients.
- Amended CDO Dr. Qing Zuraw's severance: pro-rated 2025/2026 target bonus if terminated w/o cause, or if resigns after Dec 31, 2025.
- Employment amendment effective for five months from Nov 2, 2025.

## SEC filing metadata
- accession: 0001193125-25-261723
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525261723/0001193125-25-261723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525261723/vor-20251102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261723
- JSON: https://secwatch.observer/filing/0001193125-25-261723.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.